Vincent Van Houten

Vincent van Houten is the Chief Financial Officer and a General Partner at Forbion, one of Europe's largest dedicated life-sciences venture capital firms, which manages roughly €5 billion across multiple fund strategies and employs a team of 50+ across offices in Naarden (NL), Munich (DE), and Boston (US). He joined Forbion in 2007 and was appointed CFO in January 2016. Since joining, he has played an active role in setting up and maintaining the Forbion investment funds and in the firm's corporate and fiscal (re)structuring.

As CFO he is responsible for the overall financial and fiscal matters of the Forbion group. He also sits within the investment team, where he assists on financial topics related to the portfolio. In several cases he has served directly as CFO of Forbion portfolio companies — including Staten Biotechnology B.V., NorthSea Therapeutics B.V., and Dezima Pharma B.V., where he played an active role in the 2015 sale of Dezima to Amgen. He has held finance-related roles connected to the broader Forbion network, including BioGeneration Ventures.

Van Houten holds a Master's degree (MSc) in financial management from the University of Amsterdam and has a finance and accounting background; prior to Forbion he worked at a trust office. It is worth noting that his function is that of a fund/finance principal rather than a check-writing seed investor — a founder seeking capital would typically engage Forbion's investment partners, with van Houten involved on financial structuring and fund-level matters.

• Forbion backs innovative biotech and (bio)pharmaceutical companies developing novel therapeutics, spanning all stages of drug development from company creation to clinical and growth stages.
• The firm runs distinct fund strategies: Forbion Ventures (earlier-stage), Forbion Growth Opportunities (later-stage clinical assets), and Forbion BioEconomy Fund (sustainable biotech).
• Forbion frequently leads or co-leads financings and builds/incubates companies around promising science and experienced drug developers.
• Van Houten's personal contribution to deals is on the financial/fiscal side — fund structuring, portfolio-company CFO support, and transaction execution (e.g., M&A exits) — rather than thesis-driven sourcing.